Technical Analysis for ATNF - 180 Life Sciences Corp.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| F | 1.80 | 1.76% | 0.03 |
ATNF closed up 1.76 percent on Friday, April 26, 2024, on 16 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.
Earnings due: May 13
*** please verify all earnings dates ***| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| NR7 | Range Contraction | 0.00% | |
| NR7-2 | Range Contraction | 0.00% | |
| Narrow Range Bar | Range Contraction | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| NR7 | Range Contraction | 1.76% | |
| Narrow Range Bar | Range Contraction | 1.76% | |
| Wide Bands | Range Expansion | 1.76% | |
| Gapped Down | Weakness | 1.76% | |
| Calm After Storm | Range Contraction | -1.10% | |
| Narrow Range Bar | Range Contraction | -1.10% |
| Alert | Time |
|---|---|
| Possible NR7 | about 15 hours ago |
| 10 DMA Resistance | about 16 hours ago |
| Rose Above Previous Day's High | about 18 hours ago |
| Rose Above 10 DMA | about 18 hours ago |
| Up 3% | about 18 hours ago |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/13/2024
180 Life Sciences Corp. is a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain by leveraging the combined expertise of luminaries in therapeutics from Oxford University, the Hebrew University and Stanford University. 180 Life Sciences is leading the research into solving one of the world’s biggest drivers of disease – inflammation. The Company is driving groundbreaking study into clinical programs, which are seeking to develop novel drugs addressing separate areas of inflammation for which there are no effective therapies. The Company’s primary platform is a novel program to treat fibrosis using anti-TNF, with its lead program in phase 2b/3 clinical trials.
Sector: Industrials
Industry: Conglomerates
Keywords: Biotechnology Clinical Medicine Disease Immunology Pain Inflammation Inflammatory Diseases Cytokine Fibrosis Human Physiology Tumor Necrosis Factor Animal Physiology
Classification
Sector: Industrials
Industry: Conglomerates
Keywords: Biotechnology Clinical Medicine Disease Immunology Pain Inflammation Inflammatory Diseases Cytokine Fibrosis Human Physiology Tumor Necrosis Factor Animal Physiology
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 27.93 |
| 52 Week Low | 1.33 |
| Average Volume | 130,479 |
| 200-Day Moving Average | 7.51 |
| 50-Day Moving Average | 2.85 |
| 20-Day Moving Average | 2.03 |
| 10-Day Moving Average | 1.82 |
| Average True Range | 0.35 |
| RSI (14) | 38.65 |
| ADX | 16.51 |
| +DI | 16.03 |
| -DI | 20.62 |
| Chandelier Exit (Long, 3 ATRs) | 1.97 |
| Chandelier Exit (Short, 3 ATRs) | 2.37 |
| Upper Bollinger Bands | 2.52 |
| Lower Bollinger Band | 1.54 |
| Percent B (%b) | 0.26 |
| BandWidth | 48.07 |
| MACD Line | -0.30 |
| MACD Signal Line | -0.33 |
| MACD Histogram | 0.0305 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 1.95 | ||||
| Resistance 3 (R3) | 1.96 | 1.91 | 1.93 | ||
| Resistance 2 (R2) | 1.91 | 1.88 | 1.91 | 1.92 | |
| Resistance 1 (R1) | 1.86 | 1.85 | 1.89 | 1.85 | 1.91 |
| Pivot Point | 1.81 | 1.81 | 1.83 | 1.81 | 1.81 |
| Support 1 (S1) | 1.76 | 1.78 | 1.79 | 1.75 | 1.69 |
| Support 2 (S2) | 1.71 | 1.75 | 1.71 | 1.68 | |
| Support 3 (S3) | 1.66 | 1.71 | 1.68 | ||
| Support 4 (S4) | 1.65 |
